Literature DB >> 27811122

Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study.

Tadao Aikawa1, Masanao Naya2, Masahiko Obara1, Osamu Manabe3, Yuuki Tomiyama3, Keiichi Magota4, Satoshi Yamada1, Chietsugu Katoh5, Nagara Tamaki3, Hiroyuki Tsutsui1.   

Abstract

Diastolic dysfunction is important in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). Sympathetic nervous hyperactivity may contribute to the development of diastolic dysfunction. The aim of this study was to determine the relationship between myocardial sympathetic innervation quantified by 11C-hydroxyephedrine PET and diastolic dysfunction in HFpEF patients.
Methods: Forty-one HFpEF patients having an echocardiographic left ventricular ejection fraction of 40% or greater and 12 age-matched volunteers without heart failure underwent the echocardiographic examination and 11C-hydroxyephedrine PET. Diastolic dysfunction was classified into grades 0-3 by Doppler echocardiography. Myocardial sympathetic innervation was quantified using the 11C-hydroxyephedrine retention index (RI). The coefficient of variation of 17-segment RIs was derived as a measure of heterogeneity in myocardial 11C-hydroxyephedrine uptake.
Results: Grade 2-3 diastolic dysfunction (DD2-3) was found in 19 HFpEF patients (46%). They had a significantly lower global RI (0.075 ± 0.018 min-1) than volunteers (0.123 ± 0.028 min-1, P < 0.001) and HFpEF patients with grade 0-1 diastolic dysfunction (DD0-1) (0.092 ± 0.024 min-1, P = 0.046). HFpEF patients with DD2-3 had the largest coefficient of variation of 17-segment RIs of the 3 groups (18.4% ± 7.7% vs. 14.1% ± 4.7% in HFpEF patients with DD0-1, P = 0.042 for post hoc tests). In multivariate logistic regression analysis, a lower global RI (odds ratio, 0.66 per 0.01 min-1; 95% confidence interval, 0.38-0.99; P = 0.044) was independently associated with the presence of DD2-3 in HFpEF patients.
Conclusion: Myocardial sympathetic innervation was impaired in HFpEF patients and was associated with the presence of advanced diastolic dysfunction in HFpEF.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  11C-hydroxyephedrine; diastolic dysfunction; heart failure with preserved ejection fraction

Mesh:

Substances:

Year:  2016        PMID: 27811122     DOI: 10.2967/jnumed.116.178558

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction.

Authors:  Liping Zhou; Adrian Filiberti; Mary Beth Humphrey; Christian D Fleming; Benjamin J Scherlag; Sunny S Po; Stavros Stavrakis
Journal:  Exp Physiol       Date:  2018-11-29       Impact factor: 2.969

2.  Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans.

Authors:  Nicole Tran; Zain Asad; Khaled Elkholey; Benjamin J Scherlag; Sunny S Po; Stavros Stavrakis
Journal:  J Cardiovasc Transl Res       Date:  2018-12-17       Impact factor: 4.132

3.  Imaging of the Cardiac Sympathetic Nervous System Has Potential Value in the Evaluation of Patients with Heart Failure with Preserved Ejection Fraction.

Authors:  Nabil E Boutagy; Albert J Sinusas
Journal:  J Nucl Med       Date:  2017-02-23       Impact factor: 10.057

4.  Regional interaction between myocardial sympathetic denervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study.

Authors:  Tadao Aikawa; Masanao Naya; Masahiko Obara; Noriko Oyama-Manabe; Osamu Manabe; Keiichi Magota; Yoichi M Ito; Chietsugu Katoh; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-26       Impact factor: 9.236

5.  Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Hufang Zhou; Wenhua Peng; Fuyao Li; Yuelin Wang; Baofu Wang; Yukun Ding; Qian Lin; Ying Zhao; Guozhong Pan; Xian Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-04

6.  Left Ventricular Diastolic Dysfunction in a Rat Model of Diabetic Cardiomyopathy using ECG-gated 18F-FDG PET.

Authors:  Rudolf A Werner; Christoph Eissler; Nobuyuki Hayakawa; Paula Arias-Loza; Hiroshi Wakabayashi; Mehrbod S Javadi; Xinyu Chen; Tetsuya Shinaji; Constantin Lapa; Theo Pelzer; Takahiro Higuchi
Journal:  Sci Rep       Date:  2018-12-04       Impact factor: 4.379

7.  Comparison of clinical efficacy of metoprolol combined with irbesartan and hydrochlorothiazide and non-invasive ventilator in the emergency treatment of patients with severe heart failure.

Authors:  Fangxia Zhang; Guoxia Zhou; Lisha Guo; Fei Lu; Guojun Zhou
Journal:  Exp Ther Med       Date:  2018-10-04       Impact factor: 2.447

8.  Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT.

Authors:  Yusuke Tokuda; Mamoru Sakakibara; Keiichiro Yoshinaga; Shiro Yamada; Kiwamu Kamiya; Naoya Asakawa; Takashi Yoshitani; Keiji Noguchi; Osamu Manabe; Nagara Tamaki; Hiroyuki Tsutsui
Journal:  J Nucl Cardiol       Date:  2017-11-27       Impact factor: 5.952

9.  Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction.

Authors:  Shunsuke Tamaki; Takahisa Yamada; Takashi Morita; Yoshio Furukawa; Masato Kawasaki; Atsushi Kikuchi; Tsutomu Kawai; Masahiro Seo; Makoto Abe; Jun Nakamura; Kyoko Yamamoto; Kiyomi Kayama; Masatsugu Kawahira; Kazuya Tanabe; Kunpei Ueda; Takanari Kimura; Daisuke Sakamoto; Yuto Tamura; Takeshi Fujita; Masatake Fukunami
Journal:  ESC Heart Fail       Date:  2020-04-03

10.  Radiopharmaceutical tracers for cardiac imaging.

Authors:  Osamu Manabe; Tatsuya Kikuchi; Arthur J H A Scholte; Mohammed El Mahdiui; Ryuichi Nishii; Ming-Rong Zhang; Eriko Suzuki; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2017-12-01       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.